News

January 26, 2011 – Patient enrollment has begun in China for a trial evaluating the safety and effectiveness of a next-generation stent. The PLATINUM China clinical trial will look at the Promus...

January 24, 2011 – Patient enrollment was completed in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Boston Scientific's fourth-generation Synergy...

January 20, 2011 – European CE mark approval was granted to expand the indication of Abbott’s Xience Prime everolimus-eluting coronary stent for the treatment of critical limb ischemia (CLI) or...

January 10, 2011 – European CE mark approval was announced today for the Abbott, Absorb drug-eluting bioresorbable coronary stent. It is the first bioresorbable stent to gain regulatory approval...

December 6, 2010 - A European court has struck a blow to Boston Scientific's alleged patent infringement case against OrbusNeich. The case is viewed by OrbusNeich as an unsuccessful retaliatory...

September 28, 2010 – Three-year follow-up data from the HORIZONS-AMI trial presented at Transcatheter Cardiovascular Therapeutics (TCT) 2010 last week continues to show marked improvement of...

September 24, 2010 – Drug-eluting stents are beneficial in treating symptomatic peripheral artery disease (PAD) in the femoropopliteal artery. Data from the ZILVER PTX trial demonstrate that...

September 24, 2010 - Two-year data from the SPIRIT IV trial show that everolimus-eluting stents demonstrated enhanced safety and efficacy in treating de novo native coronary artery lesions when...

September 23, 2010 - Results from the second stage of a trial studying a bioresorbable vascular scaffold were announced at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington...

September 23, 2010 - Results from a study evaluating the safety and clinical efficacy of the Promus Element everolimus-eluting coronary stent will be released at the Transcatheter Cardiovascular...

September 22, 2010 – Coronary artery disease, a leading cause of death and poor quality of life worldwide, can often complicate the daily practice of interventional cardiology. But new data from...

September 21, 2010 – A new drug-eluting stent system has received CE mark approval for diabetic patients and those experiencing a heart attack.

The PROMUS element everolimus-eluting stent...

September 20, 2010 – Patient enrollment has started in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir Medical’s novolimus-eluting coronary stent with bioabsorbable coating,...

September 14, 2010 – The latest clinical trial data for the Promus Element and Taxus Element coronary stents will be released during the Transcatheter Cardiovascular Therapeutics (TCT) scientific...

September 8. 2010 – Intravascular ultrasound (IVUS)-guided bifurcation stenting significantly reduced the four-year mortality in patients as compared to conventional angiographically guided...

September 7, 2010 – New analyses of subgroups from the SORT OUT III study provide detail on longer-term follow-up safety and efficacy outcomes in diabetics and patients with acute coronary...

September 1, 2010 - The results of follow-up tests undertaken ten years after the first patient was treated with a Cypher sirolimus-eluting coronary stent were presented at the European Society of...

September 1, 2010 - A new zotarolimus-eluting coronary stent using a biocompatible polymer gained CE mark and is being launched in Europe this week. The Medtronic Resolute Integrity Stent System...

In the world of endovascular devices, the rule is no longer one size fits all. The recent increase in the variety of stents for percutaneous coronary intervention (PCI) offers the physician of a...

August 24, 2010 – Optical coherence tomography (OCT) evaluation of a patient with anterior ST-elevation myocardial infarction (STEMI) who received two OrbusNeich Genous Bio-engineered R stents...